EP2859093A4 - Improved methods of cell culture for adoptive cell therapy - Google Patents
Improved methods of cell culture for adoptive cell therapyInfo
- Publication number
- EP2859093A4 EP2859093A4 EP13804099.3A EP13804099A EP2859093A4 EP 2859093 A4 EP2859093 A4 EP 2859093A4 EP 13804099 A EP13804099 A EP 13804099A EP 2859093 A4 EP2859093 A4 EP 2859093A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- improved methods
- cell culture
- adoptive
- cell
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011467 adoptive cell therapy Methods 0.000 title 1
- 238000004113 cell culture Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/493,768 US20130115617A1 (en) | 2009-12-08 | 2012-06-11 | Methods of cell culture for adoptive cell therapy |
PCT/US2013/045209 WO2013188427A1 (en) | 2012-06-11 | 2013-06-11 | Improved methods of cell culture for adoptive cell therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2859093A1 EP2859093A1 (en) | 2015-04-15 |
EP2859093A4 true EP2859093A4 (en) | 2016-08-17 |
Family
ID=49758673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13804099.3A Pending EP2859093A4 (en) | 2012-06-11 | 2013-06-11 | Improved methods of cell culture for adoptive cell therapy |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2859093A4 (en) |
JP (4) | JP2015519080A (en) |
CN (2) | CN104411819B (en) |
AU (3) | AU2013274416B2 (en) |
CA (1) | CA2873608A1 (en) |
IL (4) | IL302514A (en) |
SG (2) | SG11201407819UA (en) |
WO (1) | WO2013188427A1 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
AU2013274416B2 (en) * | 2012-06-11 | 2019-07-04 | Wilson Wolf Manufacturing, LLC | Improved methods of cell culture for adoptive cell therapy |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
EP2970372B1 (en) | 2013-03-15 | 2020-09-30 | Celgene Corporation | Modified t lymphocytes |
WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
SG11201701111SA (en) * | 2014-08-12 | 2017-03-30 | Anthrogenesis Corp | Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract |
CN106755023A (en) * | 2015-10-15 | 2017-05-31 | 中国人民解放军军事医学科学院附属医院 | Chimeric antigen receptor immunocyte with safety switch and preparation method and application |
GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
KR102630017B1 (en) | 2016-07-07 | 2024-01-25 | 이오반스 바이오테라퓨틱스, 인크. | Programmed death 1 ligand 1 (PD-L1) binding protein and methods of use thereof |
CN106119193B (en) * | 2016-07-28 | 2019-10-29 | 上海闪锦生物科技有限公司 | A kind of preparation method for the T cells with antigenic specificity having NK cell speciality concurrently |
EP3532607B1 (en) | 2016-10-26 | 2024-01-31 | Iovance Biotherapeutics, Inc. | Restimulation of cryopreserved tumor infiltrating lymphocytes |
TWI788307B (en) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
KR102618948B1 (en) | 2016-11-17 | 2023-12-27 | 이오반스 바이오테라퓨틱스, 인크. | Residual tumor infiltrating lymphocytes and methods of making and using the same |
EP3565888A1 (en) | 2017-01-06 | 2019-11-13 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
EP3565586A1 (en) | 2017-01-06 | 2019-11-13 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
JOP20190224A1 (en) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
JP7349365B2 (en) | 2017-05-10 | 2023-09-22 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Expansion of tumor-infiltrating lymphocytes from liquid tumors and their therapeutic use |
EP3635097A1 (en) | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
CN111601883A (en) | 2017-11-17 | 2020-08-28 | 艾欧凡斯生物治疗公司 | TIL amplification from Fine needle aspirates and Small biopsies |
EP3714041A1 (en) | 2017-11-22 | 2020-09-30 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
JP2021508104A (en) | 2017-12-15 | 2021-02-25 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Systems and methods for determining beneficial administration of tumor-infiltrating lymphocytes and their use, as well as beneficial administration of tumor-infiltrating lymphocytes and their use. |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
KR20200119242A (en) | 2018-01-08 | 2020-10-19 | 이오반스 바이오테라퓨틱스, 인크. | Methods of generating TIL products enriched for tumor antigen-specific T-cells |
KR20200138329A (en) | 2018-03-29 | 2020-12-09 | 이오반스 바이오테라퓨틱스, 인크. | Method for producing tumor-infiltrating lymphocytes and their use in immunotherapy |
MX2020011134A (en) | 2018-04-27 | 2020-11-11 | Iovance Biotherapeutics Inc | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy. |
WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
TW202031273A (en) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | Treatment of nsclc patients refractory for anti-pd-1 antibody |
BR112021003678A2 (en) | 2018-09-20 | 2021-05-18 | Iovance Biotherapeutics, Inc. | methods for cryopreserving tumor tissue, for manufacturing, for preparing and for expanding tumor infiltrating lymphocytes, for treating a subject with cancer and for treating cancer for a human subject, and, cryopreserved tumor fragment. |
CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
JP2022512899A (en) | 2018-11-05 | 2022-02-07 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of NSCLC patients refractory to anti-PD-1 antibody |
AU2019374761A1 (en) | 2018-11-05 | 2021-06-10 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
CN113272420A (en) | 2018-11-05 | 2021-08-17 | 艾欧凡斯生物治疗公司 | Improved selection of tumor-reactive T cells |
CA3123392A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
WO2021081378A1 (en) | 2019-10-25 | 2021-04-29 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
CA3161104A1 (en) | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
AU2020408017A1 (en) | 2019-12-20 | 2022-07-14 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
CA3176356A1 (en) | 2020-04-22 | 2021-10-28 | Anne BROOKS | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
TW202208617A (en) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
EP4146793A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
EP4259164A1 (en) | 2020-12-11 | 2023-10-18 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
JP2023554395A (en) | 2020-12-17 | 2023-12-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment with tumor-infiltrating lymphocyte therapy in combination with CTLA-4 and PD-1 inhibitors |
EP4326287A2 (en) | 2021-04-19 | 2024-02-28 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
AR127482A1 (en) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011072088A2 (en) * | 2009-12-08 | 2011-06-16 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
WO2012138858A1 (en) * | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731160A (en) * | 1992-05-26 | 1998-03-24 | Rijksuniversiteit Leiden | Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines |
US20030235908A1 (en) * | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
US7638325B2 (en) * | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
US7745140B2 (en) * | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
CA2525519A1 (en) * | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
WO2007017201A1 (en) * | 2005-08-05 | 2007-02-15 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | Generation of antigen specific t cells |
JP2009213462A (en) * | 2008-02-15 | 2009-09-24 | Kist-Europe Forschungs Gmbh | Cell modification method and cell modification device |
EP2470644B1 (en) * | 2009-08-24 | 2016-09-21 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
US20130115617A1 (en) * | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
WO2013035099A1 (en) * | 2011-09-08 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
WO2013088114A1 (en) * | 2011-12-12 | 2013-06-20 | Cell Medica Limited | Process of expanding t cells |
GB201121308D0 (en) * | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
PT2812431T (en) * | 2012-02-09 | 2019-10-18 | Baylor College Medicine | Pepmixes to generate multiviral ctls with broad specificity |
US20130217122A1 (en) * | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
CN102719399A (en) * | 2012-04-28 | 2012-10-10 | 北京爱根生物科技有限公司 | In vitro amplification method of self-specific T cell, prepared T cell system, pharmaceutical use of cell system and component monitoring method of cell system |
EP2850175B1 (en) * | 2012-05-18 | 2020-12-16 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
AU2013274416B2 (en) * | 2012-06-11 | 2019-07-04 | Wilson Wolf Manufacturing, LLC | Improved methods of cell culture for adoptive cell therapy |
CN105593362B (en) * | 2013-09-23 | 2021-09-10 | 威尔逊沃夫制造公司 | Improved method for genetically modifying animal cells |
US10857182B2 (en) * | 2016-09-23 | 2020-12-08 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory T cells |
TW201814042A (en) * | 2016-09-26 | 2018-04-16 | 新加坡商泰莎治療私人有限公司 | T cell expansion method |
US20210147801A1 (en) * | 2017-07-13 | 2021-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregs |
EP4003378A4 (en) * | 2019-07-29 | 2023-08-23 | Baylor College of Medicine | Antigen-specific t cell banks and methods of making and using the same therapeutically |
KR20220048021A (en) * | 2019-08-16 | 2022-04-19 | 베이롤 칼리지 오브 메드신 | Third party virus-specific T cell compositions, methods for their preparation and methods for their use in antiviral prophylaxis |
US20210371822A1 (en) * | 2020-05-27 | 2021-12-02 | University Of Southern California | Methods for expanding sars-cov2-antigen-specific t cells, compositions and uses related thereto |
-
2013
- 2013-06-11 AU AU2013274416A patent/AU2013274416B2/en active Active
- 2013-06-11 JP JP2015517361A patent/JP2015519080A/en active Pending
- 2013-06-11 SG SG11201407819UA patent/SG11201407819UA/en unknown
- 2013-06-11 WO PCT/US2013/045209 patent/WO2013188427A1/en active Application Filing
- 2013-06-11 IL IL302514A patent/IL302514A/en unknown
- 2013-06-11 CN CN201380030610.XA patent/CN104411819B/en active Active
- 2013-06-11 EP EP13804099.3A patent/EP2859093A4/en active Pending
- 2013-06-11 CA CA2873608A patent/CA2873608A1/en active Pending
- 2013-06-11 SG SG10201610387QA patent/SG10201610387QA/en unknown
- 2013-06-11 CN CN201910301618.4A patent/CN110241086A/en active Pending
- 2013-06-11 IL IL288241A patent/IL288241B2/en unknown
-
2014
- 2014-11-17 IL IL235739A patent/IL235739B/en active IP Right Grant
-
2018
- 2018-06-15 JP JP2018114352A patent/JP2018138059A/en active Pending
-
2019
- 2019-10-03 AU AU2019240684A patent/AU2019240684A1/en not_active Abandoned
-
2020
- 2020-03-31 IL IL273719A patent/IL273719B/en unknown
- 2020-08-07 JP JP2020134448A patent/JP7244461B2/en active Active
-
2022
- 2022-03-30 AU AU2022202172A patent/AU2022202172A1/en active Pending
-
2023
- 2023-03-08 JP JP2023035371A patent/JP2023065668A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011072088A2 (en) * | 2009-12-08 | 2011-06-16 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
WO2012138858A1 (en) * | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
Non-Patent Citations (3)
Title |
---|
JUAN F VERA ET AL: "Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9 | Blood Journal", BLOOD, vol. 112, no. 11, 16 November 2008 (2008-11-16), US, pages 1211 - 1211, XP055286020, ISSN: 0006-4971 * |
T. FEUCHTINGER ET AL: "Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation", BLOOD, vol. 116, no. 20, 18 November 2010 (2010-11-18), US, pages 4360 - 4367, XP055247973, ISSN: 0006-4971, DOI: 10.1182/blood-2010-01-262089 * |
YOZO NAKAZAWA ET AL: "PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor", MOLECULAR THERAPY, vol. 19, no. 12, 19 July 2011 (2011-07-19), GB, pages 2133 - 2143, XP055282256, ISSN: 1525-0016, DOI: 10.1038/mt.2011.131 * |
Also Published As
Publication number | Publication date |
---|---|
CA2873608A1 (en) | 2013-12-19 |
SG11201407819UA (en) | 2014-12-30 |
JP2015519080A (en) | 2015-07-09 |
IL235739A0 (en) | 2015-01-29 |
IL235739B (en) | 2020-04-30 |
AU2019240684A1 (en) | 2019-10-24 |
AU2013274416B2 (en) | 2019-07-04 |
IL302514A (en) | 2023-07-01 |
JP7244461B2 (en) | 2023-03-22 |
IL288241B2 (en) | 2023-10-01 |
AU2022202172A1 (en) | 2022-04-21 |
IL288241B1 (en) | 2023-06-01 |
JP2020174685A (en) | 2020-10-29 |
CN104411819A (en) | 2015-03-11 |
JP2018138059A (en) | 2018-09-06 |
WO2013188427A1 (en) | 2013-12-19 |
IL273719A (en) | 2020-05-31 |
SG10201610387QA (en) | 2017-02-27 |
CN110241086A (en) | 2019-09-17 |
IL288241A (en) | 2022-01-01 |
AU2013274416A1 (en) | 2015-01-15 |
JP2023065668A (en) | 2023-05-12 |
EP2859093A1 (en) | 2015-04-15 |
IL273719B (en) | 2022-01-01 |
CN104411819B (en) | 2019-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288241A (en) | Improved methods of cell culture for adoptive cell therapy | |
IL271005A (en) | Improved methods of cell culture for adoptive cell therapy | |
HK1210494A1 (en) | Devices and methods for culture of cells | |
HK1199905A1 (en) | Culturing of mesenchymal stem cells | |
IL220232A0 (en) | Improved methods of cell culture for adoptive cell therapy | |
IL236672B (en) | System and methods for preparation of adipose-derived stem cells | |
EP2861612A4 (en) | Methods of preparing pluripotent stem cells | |
EP2968549A4 (en) | Methods of cell culture | |
EP2971014A4 (en) | Methods of cell culture | |
EP2971040A4 (en) | Methods of cell culture | |
PT2683815E (en) | Genetically modified cell and process for use of said cell | |
SG11201503579RA (en) | Cell culture med | |
GB201100180D0 (en) | Tumour cell and tissue culture | |
HK1208727A1 (en) | Tumor cell isolation purification process and methods for use thereof | |
SG10201700670WA (en) | Cell culture | |
EP2860239A4 (en) | Vessel for culturing human es cells | |
GB2520899B (en) | Method for discriminating differentiation degree of pluripotent stem cell | |
GB201211873D0 (en) | Cell culture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20141229 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/0783 20100101AFI20160217BHEP Ipc: A61K 39/12 20060101ALI20160217BHEP Ipc: A61K 35/12 20060101ALI20160217BHEP |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20160715 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/0783 20100101AFI20160712BHEP Ipc: A61K 39/12 20060101ALI20160712BHEP Ipc: A61K 35/12 20060101ALI20160712BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180221 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20231208 |